Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

As Amgen waits for an FDA decision on a second indication for its B cell-depleting therapy Uplizna, it has new data suggesting a third may be coming down the pipe. New data from the phase 3 MINT ...

Horizon Therapeutics Plc presented positive new MRI data from the phase 3 clinical trial of UPLIZNA (inebilizumab) at the 9th Congress of the European Academy of Neurology (EAN) in Budapest ...

DelveInsight's B-cell Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable ...

Defining and categorizing long COVID has confounded clinicians and researchers since the condition was first identified in the throes of the pandemic, and the challenge continues today. Move over ...

Advancements in gene therapy for Duchenne muscular dystrophy (DMD) have improved the outlook for some patients, but further innovations in safety, efficacy, and treatment strategies are needed.

US-based Ariad Pharmaceuticals is focused on discovering, developing and commercializing precision therapies for patients with rare cancers. Ariad is working on new medicines to advance the treatment ...